NCT00262873View on ClinicalTrials.gov

Bortezomib in Treating Patients With Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

bortezomib

Trial Locations (1)

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT00262873 - Bortezomib in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter